EXPERIENCE OF USING DRUG TOCILIZUMAB IN A BOY WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/pf.v10i6.901
Abstract
The article presents a case of complicated diagnostics of systemic juvenile idiopathic (rheumatoid) arthritis (JIA) starting with a fever of unclear genesis. Efficacy of interleukin 6 inhibitor tocilizumab for treating the systemic JIA resistant to glucocorticosteroid and methotrexate therapy is shown.
About the Authors
E. S. Zholobova
First Sechenov Moscow State Medical University
Russian Federation
PhD, Professor at the department of childhood diseases at the First Sechenov MSMU
Russian Federation
PhD, Professor at the department of childhood diseases at the First Sechenov MSMU
E. S. Zholobova
First Sechenov Moscow State Medical University
Russian Federation
Russian Federation
References
1. Alekseeva E. I. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Pod obshch. red. A.A. Baranova [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Features, Diagnosis and Treatment Algorithms. Edited by A.A. Baranov]. Moscow, VEDI, 2007. 360 p.
2. Zholobova E. S., Shakhbazyan I. E., Ulybina O. V. Yuvenil'nyi revmatoidnyi artrit. Rukovodstvo po detskoi revmatologii. Pod redaktsiei N. A. Geppe, N. S. Podchernyaevoi, G. A. Lyskinoi [Juvenile Rheumatoid Arthritis. Guidelines for Pediatric Rheumatologist. Edited by N. A. Geppe, N. S. Podchernyaeva, G. A. Lyskina]. Moscow, GEOTAR-Media, 2011. pp. 162–245.
3. Beukelman T., Patkar N. M., Saag K. G. et al. 2011 American College of Rheumatology. Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Research. April 2011; 63 (4): 465–482.
4. Bzarova T. M., Alekseeva E. I., Peterkova V. A. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (5): 13–18.
5. Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.
6. Alexeeva E., Denisova R., Valieva S., Bzarova T., Isayeva K., Sleptsova T., Mitenko E. Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 202.
7. De Benedetti F., Brunner H. I., Ruperto N., Kenwright A. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367 (25): 2385–2395.
8. Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 719.
9. Russo R., Katsicas M. Tocilizumab in jia patients who have inadequate response to anti-tumour necrosis factor therapy. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 186.
10. Sawhney S., Aggarwal M. Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India. Pediatr. Rheumatol. Online J. 2012; 10 (Suppl. 1): 49.
11. Smolen J. S., Schoels M. M., Nishimoto N. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin n-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 2013; 72 (4): 482–492.
12. Yokota S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.
13. Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.
14. Yokota S., Tanaka T., Kishimot T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther. Adv. Musculoskelet Dis. 2012; 4 (6): 387–397.
Review
For citations:
Zholobova E.S., Zholobova E.S. EXPERIENCE OF USING DRUG TOCILIZUMAB IN A BOY WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. Pediatric pharmacology. 2013;10(6):82-84. https://doi.org/10.15690/pf.v10i6.901
Views:
926
Email this article 